Please login to the form below

Not currently logged in
Email:
Password:

Pierre Fabre

This page shows the latest Pierre Fabre news and features for those working in and with pharma, biotech and healthcare.

Pierre Fabre’s Braftovi scores NICE backing for BRAF+ colorectal cancer

Pierre Fabre’s Braftovi scores NICE backing for BRAF+ colorectal cancer

Drug approved in combination with Merck's KGaA's Erbitux. French pharma group Pierre Fabre’s Braftovi has been recommended for NHS use by the UK’s National Institute for Health ... Pierre Fabre is also looking to prove the Braftovi/Mektovi

Latest news

More from news
Approximately 1 fully matching, plus 16 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics